Nabsys Showcases OhmX™ Platform Advances at ASHG 2025 Meeting

Nabsys 2.0, a leading innovator in electronic genome mapping, presented groundbreaking findings at the American Society of Human Genetics (ASHG) Annual Meeting held from October 14-18, 2025, in Boston, Massachusetts. Their focus was on the OhmX™ Platform, which demonstrates a remarkable capacity for accurately verifying structural variants, especially in undiagnosed disorders. This technology has the potential to transform diagnostic capabilities in clinical settings.

The session, held in collaboration with Boston Children's Hospital, emphasized real-world applications of the OhmX Platform. Dr. Catherine Brownstein, from Boston Children's Hospital, noted that Nabsys' electronic genome mapping technology offers high-resolution analysis of genome-wide structural variation. This advancement enables researchers to gain insights into structural variations that were previously undetectable, thus playing a crucial role in understanding the etiology of rare or challenging to diagnose diseases.

Barrett Bready, M.D., founder and CEO of Nabsys, expressed excitement about presenting critical research that underscores the real-world impact of the OhmX Platform on scientific inquiry. He emphasized the platform's commitment to speed, accessibility, and precision in analyzing whole-genome structural variations. Bready also hinted at forthcoming data that would further illustrate how this platform is reshaping genome mapping methodologies.

A standout presentation featured a poster titled "Accelerated Electronic Genome Mapping with Simultaneous Dual Nicking Labeling Boosting Structural Variant Calling on the OhmX Platform" (Poster # 4089W). This study highlighted an innovative simultaneous dual nicking and labeling (SNL) chemistry that enhances workflow for electronic genome mapping, drastically reducing the time and complexity involved in DNA labeling while simultaneously improving assembly and structural variant calling.

Nabsys found a significant improvement with a 1.8-fold increase in assembly contiguity and a 24% improvement in structural variant recall when comparing results obtained through the new SNL method against traditional workflows. These advancements not only enhance the efficiency of the mapping process but also maintain equivalent precision, crucial for delivering quality results in critical clinical situations.

Dr. Jay Sage, Senior Director of Assay Development at Nabsys, explained that optimizing EGM technology workflows is vital for decreasing both user variability and the time it takes from sample to actionable results. This is particularly important in settings where time-sensitive decisions are necessary, such as prenatal diagnostics. The ability to achieve quicker results without compromising the integrity of the analysis marks a significant leap forward for diagnostic technologies.

As Nabsys continues to refine its methods, the company is poised to revolutionize genomic analysis through its innovative technologies. The presentations from the ASHG meeting, encompassing eight separate EGM studies, highlight the company's pledge to advance the understanding of genetic diseases, enhance diagnostic yield, and ultimately improve patient outcomes.

For those interested in a deep dive into the presentations and technologies discussed, Nabsys has made available all materials related to the event on their official website's resource section.

As the company moves forward, the integration of the OhmX Platform and its novel chemical strategies promises to not just streamline processes but also provide a comprehensive view of the human genome. This could lead to more accurate diagnoses and targeted treatments for a variety of genetic disorders, thereby paving the way for advances in personalized medicine that could greatly benefit patients globally.